[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-resectable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-resectable":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,51,88,116,138,164,195,231,258,301,325,356,384,408,435,453,477,498,523,544,569,597,617,643],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100054022","phase-1-egfr-targeted-photoimmunotherapy-with-asp-1929-for-locally-advanced-pancreatic-cancer-100054022",false,"NCT07698613","EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","BrUOG 438: EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n1. Pathologically confirmed pancreatic adenocarcinoma.\n2. Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.\n3. Completed neoadjuvant chemotherapy\n4. Neoadjuvant radiation is allowed\n5. Planned surgical exploration\n6. Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.\n7. Patients with a history of biliary obstruction must have adequate biliary drainage.\n8. Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:\n\n   Platelet Count ≥ 75,000\u002Fmm3. Hemoglobin ≥ 8.0 g\u002FdL \\[NOTE: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g\u002FdL are not eligible\\] Absolute neutrophil count ≥ 1,000\u002Fmm3. \\[Granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1\\] Alanine aminotransferase (ALT) ≤ 3×ULN Aspartate aminotransferase (AST) ≤ 3×ULN Total Bilirubin ≤ 1.5×ULN or \\\u003C 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) Creatinine ≤ 3×ULN\n9. Age ≥ 18\n10. ECOG performance status 0-1\n11. For women of pregnancy potential, a negative pregnancy test within 7 days prior to registration.\n12. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with distant metastases.\n2. Patients with medical co-morbidities that make them not candidates for surgical exploration\n3. Planned concomitant, non-protocol directed anti-cancer therapy for at least 8 weeks after ASP-1929\n4. Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2.\n5. History of significant (Grade ≥ 3) cetuximab infusion reactions\n6. Photosensitizing medications must be discontinued 4 weeks before ASP-1929 PIT treatment, unless medically required.\n7. No uncontrolled intercurrent illness including but not limited to symptomatic CHF, unstable angina, clinically significant severe cardiac arrhythmia, psychiatric illness or social situations that would limit compliance with study requirements.\n8. Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive ASP-1929 and\u002For be exposed to PIT illumination.\n9. Women who are pregnant or nursing.\n10. Patients with concomitant malignancies not expected to cause death within 5 years are eligible.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.",[27,28,29],"Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection","Pancreatic Cancer Borderline","Pancreatic Cancer Resectable",[31,32,33,34,35,36,37],"ASP-1929","photoimmunotherapy","EGFR targeting antibody","laser-light activable dye IR700","IRDye 700DX","RM-1929","cetuximab sarotalocan","NOT_YET_RECRUITING","2026-07-07",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":20},"2026-09",{"date":46,"type":20},"2033-09",{"name":48,"class":49},"Brown University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100633664","association-between-chronic-psychological-stress-and-disease-course-outcomes-in-pancreatic-cancer-100633664","NCT07529626","Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer","A Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)","MIND-PANC","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed diagnosis of pancreatic cancer, or other pancreatic diseases.\n* Conscious, with basic reading\u002Fwriting or communication skills, able to understand and complete the questionnaire assessments (either independently, with assistance from research staff, or with help from a family member).\n* Voluntarily agree to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe cognitive impairment (e.g., dementia, disturbance of consciousness) or a definite history of psychiatric disorders, judged by the investigator as unable to comply with the study assessments, and without a family member who can help complete the questionnaire assessments.\n* Presence of other severe, uncontrolled systemic diseases (e.g., severe heart, lung, or kidney failure), with an estimated life expectancy \\\u003C 3 months as judged by the investigator.\n* Inability to understand Chinese or presence of severe visual\u002Fhearing impairment that affects completion of the questionnaire assessments, and without a family member who can help complete the questionnaire assessments.",{"count":60,"type":20},320,"3 Years","OBSERVATIONAL","This is a prospective, observational cohort study (MIND-PANC) to explore the associations of chronic psychological stress with disease progression, treatment outcomes, and prognosis of pancreatic cancer.\n\nResearchers will ask participants to fill out simple questionnaires about their mood, worries, and sleep at the start of the study and at regular follow-up visits. The study will also collect a small blood sample (leftover from routine care) to measure stress-related markers.\n\nInvestigators hypothesize that pancreatic cancer patients who have higher levels of ongoing psychological stress (such as anxiety, depression, or poor sleep) tend to have shorter survival times, a higher chance of recurrence, and a poorer response to treatment, compared to patients with lower stress levels.",[65,66,29],"Pancreatic Tumor, Benign","Pancreatic Cancer, Adult",[68,69,70,71,72,73,74,75,76],"pancreatic cancer","anxiety","depression","psychological distress","Hospital Anxiety and Depression Scale","Pittsburgh Sleep Quality Index","disease progression","Overall survival","quality of life","RECRUITING","2026-06-24",{"date":80,"type":42},"2026-06-29",{"date":82,"type":42},"2026-05-11",{"date":84,"type":20},"2028-12-31",{"name":86,"class":49},"Shanghai Zhongshan Hospital",3,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100637776","a-trial-using-transcriptomic-signatures-to-personalize-neoadjuvant-chemotherapy-nac-for-patients-with-resectable-borderline-pancreatic-adenocarcinoma-pdac-100637776","NCT07592819","A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)","A Multicenter Randomized Phase II Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)","PRODIGE 104 B","Inclusion Criteria:\n\n* Borderline-resectable pancreatic ductal adenocarcinoma (BR-PDAC) as defined by the National Comprehensive Cancer Network (NCCN) v2.2025 criteria, identified on contrast-enhanced CT scan and reviewed by a local multidisciplinary pancreatic expert board including at least a medical oncologist \u002F onco-gastroenterologist, a pancreatic surgeon, and an expert pancreatic radiologist. No central review required.\n* WHO Performance Status 0-1.\n* Histologically confirmed pancreatic ductal adenocarcinoma, including histological variants.\n* Patient included-but not randomized-in the PRODIGE 104 A NEOPREDICT study due to a negative gemcitabine sensitivity signature (GEM-).\n* Negative gemcitabine transcriptomic signature (test centrally performed in PRODIGE 104 A NEOPREDICT).\n* No prior chemotherapy or radiotherapy for pancreatic cancer, and no previous definitive pancreatic cancer resection (except one cycle of mFOLFIRINOX administered while awaiting the signature result).\n* Age \\> 18 years and \\\u003C 80 years, with the possibility to include patients aged 75-80 if a standardized geriatric assessment confirms eligibility for the study chemotherapy regimen.\n* Ability and willingness to comply with protocol requirements during the entire study period (treatment, scheduled visits, clinical and biological examinations, follow-up).\n* Patient's non-opposition to participation in the study.\n* Affiliation to the French national health insurance system.\n\nExclusion Criteria:\n\n* Strictly resectable or locally advanced PDAC according to NCCN criteria.\n* Distant metastases, including inter-aortocaval lymph nodes.\n* Any condition contraindicating the use of irinotecan, oxaliplatin, or 5-FU.\n* Complete dihydropyrimidine dehydrogenase (DPD) deficiency.\n* Any uncontrolled or unstable medical condition within the past 6 months (e.g., hepatic, renal, respiratory, or cardiac insufficiency).\n* Another concomitant malignancy or history of cancer within the past 3 years, except for adequately treated carcinoma in situ of the cervix or basal\u002Fsquamous cell skin carcinoma.\n* Pregnancy or breastfeeding.\n* Patients under legal protection, guardianship, curatorship, or under judicial\u002Fadministrative protection.\n* Patients receiving psychiatric care or unable to provide consent.\n* Inability to comply with medical follow-up for geographical, social, or psychological reasons.","80 Years",{"count":98,"type":20},367,[100],"NA","Pancreatic cancer exhibits significant heterogeneity, which poses a major challenge in selecting the best treatment for patients from the very beginning of care. Modern oncology recognizes the use of companion biomarkers to guide targeted therapy or immune checkpoint inhibitors. However, with regard to chemotherapy-which has long been the cornerstone of cancer treatment and remains crucial for most cancers-few predictive tests are available to guide the choice between monotherapy and combination chemotherapy.\n\nPatients included in the PRODIGE 104 B - NEOPREDICT study will be those for whom the GEM transcriptomic signature is negative. This population will be treated according to the standard strategy and will be followed clinically and biologically to describe and identify the characteristics specific to this subgroup, and to compare the usual prognostic factors of this population with those of the GEM-positive population included in the parallel PRODIGE 104 A - NEOPREDICT study",[103,29],"Pancreas Adenocarcinoma (MSI-H)",[105,106,107],"Transcriptomic-guided chemotherapy","Borderline-resectable pancreatic cancer","Predictive biomarker validation",{"date":109,"type":42},"2026-05-18",{"date":111,"type":20},"2026-05",{"date":113,"type":20},"2031-11",{"name":115,"class":49},"Institut Paoli-Calmettes",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100630531","phase-1-open-label-phase-1-clinical-trial-of-neoadjuvant-nogapendekin-alfa-inbakicept-sotevtamab-and-zabadinostat-in-combination-with-gemcitabine-and-nab-paclitaxel-for-participants-with-borderline-resectable-or-locally-advanced-pancreatic-cancer-100630531","NCT07488884","Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","ResQ108B-PANC","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.\n3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n4. Histologically or cytologically confirmed PDAC that is confined to the pancreas.\n5. Borderline resectable (surgical resection possible but challenging) or locally advanced (surgical resection not possible) PDAC, as determined by the local investigator based onlocal institutional guidelines.\n6. Measurable tumor lesions according to RECIST v1.1. (within 90 days prior to first dose of study treatment).\n7. Have not received prior anticancer therapy for pancreatic cancer.\n8. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.\n9. Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. Female participants of child-bearing potential must agree to use effective contraception for up to 7 months after completion of therapy, and nonsterile male participants must agree to use a condom for up to 7 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and hormonal therapy.\n\nExclusion Criteria:\n\n1. Resectable PDAC, meeting the following criteria upon CT\u002FMRI: (a)No superior mesenteric vein (SMV) or portal vein (PV) distortion; (b) Clear fat planes around superior mesenteric artery (SMA), celiac artery (CA), and common hepatic artery (CHA).\n2. Participants for whom an operation is not considered in the participant's best interest (eg, due to comorbidity).\n3. Histologically or cytologically confirmed pancreatic tumor that is not adenocarcinoma.\n4. CA19-9 \\> 1,000 U\u002FmL.\n5. QTc interval using Fridericia's formula (QTcF) \\> 470 ms.\n6. If participants have had major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment.\n7. Have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed.\n8. Have known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n9. Inadequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to baseline: (a) Absolute neutrophil count (ANC) \\\u003C 1,500 cells\u002FμL without granulocyte colonystimulating factor support, (b) Lymphocyte count \\\u003C 500\u002FμL, (c) platelet count \\\u003C 100,000\u002FμL without transfusion (d) Hemoglobin \\\u003C 8.0 g\u002FdL Note: Participants may be transfused to meet this criterion, (e) International Normalized Ratio (INR) or aPTT activated partial thromboplastin time (aPTT) \\\u003C 1.5 × upper limit of normal (ULN) Note: This applies only to participants who are not receiving therapeutic anticoagulation; participants receiving therapeutic anticoagulation should be on a stable dose. (f) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \\> 2.5 × ULN, with the following exception: Participants with documented liver metastases: AST and\u002For ALT \\> 5 × ULN. (g) Serum bilirubin ≤ 3 × ULN (h) Creatinine clearance ≤ 60 mL\u002Fmin (calculated using the Cockcroft-Gault formula), (i) Serum albumin ≤ 3.0 g\u002FdL. (j) Urine dipstick for proteinuria \\> 2+ (within 7 days prior to initiation of study treatment). Participants with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\\u003C 1 g of protein in 24 hours.\n10. Significant cardiovascular disease (such as New York Heart Association cardiac disease class II or greater), myocardial infarction within 3 months prior to baseline, unstable arrhythmias, or unstable angina.\n11. Severe infections at the time of enrollment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n12. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Participants receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n13. Prior allogeneic bone marrow transplantation or solid organ transplant.\n14. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk for treatment complications.\n15. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.\n16. Treatment with systemic immunosuppressive medications (including, but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to initiation of study treatment, or anticipation of the need for systemic immunosuppressive medication during study treatment, with the following exceptions: (a) A. Participants who have received acute, low-dose, systemic immunosuppressant medications (eg, a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Medical Monitor, (b)B. The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (eg, fludrocortisone) for participants with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.\n17. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to the start of treatment on this study.\n18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.\n19. Pregnant and nursing women.",{"count":19,"type":20},[23],"This is an open-label, phase 1 clinical trial to evaluate the safety and preliminary efficacy of neoadjuvant chemoimmunotherapy (NAI, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel) followed by resection and adjuvant immunotherapy for participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Eligible participants will undergo endoscopic ultrasound (EUS)-guided biopsies of the primary pancreatic tumor within 7 days of enrollment and prior to study day 1. EUS-guided biopsies will be used for histopathological examination to give clinical diagnostic information (as SoC) and will be stored in an ethically approved tissue bank.",[29,127],"Pancreatic Cancer","2026-04-28",{"date":130,"type":42},"2026-04-29",{"date":132,"type":20},"2026-06-01",{"date":134,"type":20},"2029-06-01",{"name":136,"class":137},"ImmunityBio, Inc.","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":50},"100629077","phase-2-surufatinib-plus-mfolfirinox-and-pd-1-inhibitor-as-the-neoadjuvant-therapy-for-high-risk-or-borderline-resectable-pancreatic-cancer-100629077","NCT07469956","Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","Neoadjuvant Therapy With Surufatinib Combined With mFOLFIRINOX and Toripalimab for High-risk or Borderline Resectable Pancreatic Cancer: A Phase II, Single-arm, Single-center Study","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Ages 18-75 years, no gender restrictions.\n3. Patients with high-risk resectable or borderline resectable pancreatic cancer confirmed by pathological tissue or cytology:\n\n   * High-risk features include: ① Imaging findings; ② Significant elevation of CA 19-9 (baseline \\>210 U\u002Fml, Vincent P Groot, Ann Surg. 2019 Jun;269(6):1154-1162); ③ Large primary tumor (\\>3 cm, Vincent P Groot, Ann Surg. 2019 Jun;269(6):1154-1162); ④ Large regional lymph nodes (it is recommended to use imaging to assess lymph node metastasis, or if the number of metastatic lymph nodes \\>3, N2 stage); ⑤ Excessive weight loss (more than 5 kg within 1 month); ⑥ Severe pain (main complaint of abdominal pain is sufficient).\n   * Definition of borderline resectable: ① Arteries: Tumor contact with the celiac trunk (≤180°) or superior mesenteric artery (SMA) (≤180°), or involvement of the hepatic artery that is reconstructable. ② Veins: Narrowing or occlusion of the superior mesenteric vein (SMV)\u002Fportal vein (PV), but the proximal\u002Fdistal vessels are suitable for reconstruction.\n4. The patient must have at least one measurable lesion (RECIST 1.1).\n5. No BRCA1\u002F2 or PALB2 mutations.\n6. Has not previously received systemic therapy or local radiotherapy.\n7. ECOG performance status 0-1;\n8. Expected survival ≥24 weeks;\n9. No surgical contraindications;\n10. Blood tests (without transfusion in the past 14 days) 1) Absolute neutrophil count ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, hemoglobin concentration ≥9 g\u002FdL; 2) Liver function tests (AST and ALT ≤2.5×ULN, total bilirubin ≤1.5×ULN; if there are liver metastases, AST and ALT ≤5×ULN); 3) Kidney function (serum creatinine ≤1.5×ULN, creatinine clearance (CCr) ≥60 ml\u002Fmin); 4) Coagulation, international normalized ratio (INR) ≤1.5×ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n11. Male or female patients of reproductive potential voluntarily use effective contraception during the study period and for 6 months after the last study treatment, such as dual-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered of reproductive potential unless the female patient is naturally menopausal, has undergone induced menopause, or has had sterilization procedures (such as hysterectomy, bilateral salpingo-oophorectomy, or ovarian irradiation).\n\nExclusion Criteria:\n\n1. Patients with distal metastasis;\n2. Received blood transfusion therapy, blood products and hematopoietic factors such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;\n3. Received any surgical or invasive treatment or operation within 4 weeks prior to enrollment (except for intravenous catheterization, puncture and drainage, etc.);\n4. Known allergy to any drug in the study;\n5. Presence of hypertension that cannot be controlled by medication, as prescribed as: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg;\n6. The patient currently has any disease or condition that affects the absorption of the drug, or the patient has difficulty swallowing and cannot take surufatinib orally;\n7. Patients currently have active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases or active bleeding from unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the investigator;\n8. Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture methods as judged by the investigator);\n9. Patients with obvious evidence or history of bleeding tendency within 3 months before enrollment (bleeding \\>30 mL within 3 months, with hematemesis, black feces, blood in the stool), hemoptysis (\\>5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke events and\u002For transient ischemic attack) within 10 months;\n10. Clinically significant electrolyte abnormalities judged by the investigator;\n11. Significant clinically significant cardiovascular disease, including but not limited to the following: acute myocardial infarction, severe\u002Funstable angina, or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure New York Heart Association (NYHA) grade \\>2; ventricular arrhythmias requiring medication; LVEF (left ventricular ejection fraction) \\\u003C 50%;\n12. Other malignant tumors within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;\n13. Active or uncontrolled serious infection:\n\n1\\) Known human immunodeficiency virus (HIV) infection; 2) Known history of clinically significant liver disease, including viral hepatitis \\[for known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, i.e., HBV DNA positive (\\>1×10\\^4 copies\u002FmL or \\>2000 IU\u002FmL)\\]; 3) Known hepatitis C virus (HCV) infection with HCV RNA positive (\\>1×10\\^3 copies\u002FmL), or other hepatitis, cirrhosis; 14. Women who are pregnant (tested positive for pregnancy before taking the medication) or are currently breastfeeding; 15. Subjects whom the investigator considers unsuitable for participation in this clinical study due to any clinical or laboratory abnormalities or other reasons; 16. Those with routine urine test indicating urinary protein ≥2, and 24-hour urine protein quantification \\>1.0g;","75 Years",{"count":19,"type":20},[24],"The goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic cancer. It will also learn about the safety of the combination regimen. The main questions it aims to answer are:\n\nDoes the treatment regimen of surufatinib combined with immunotherapy and chemotherapy could provide further survival benefits for patients with high-risk resectable or borderline resectable pancreatic cancer as neoadjuvant therapy?\n\nIs the safety of this combination therapy tolerable?\n\nParticipants will:\n\nTake surufatinib (200mg, qd, po, q2w), Toripalimab (3mg\u002Fkg, iv, d1, q2w), Oxaliplatin (68 mg\u002Fm², iv, d1, q2w), Irinotecan (135 mg\u002Fm², iv, d1, q2w), Calcium folinate (400 mg\u002Fm², iv, d1, q2w), 5-FU (2400 mg\u002Fm², iv). Treatment for up to 8 cycles.\n\nVisit the clinic once every 8 weeks (± 7 days) for checkups and tests. Keep a diary of their symptoms and record daily medication doses.",[29],[151,152,153,154],"Surufatinib","Toripalimab","Pancreatic cancer","Resectable","2026-03-09",{"date":157,"type":42},"2026-03-13",{"date":159,"type":20},"2026-03-31",{"date":161,"type":20},"2029-01-31",{"name":163,"class":49},"Sun Yat-sen University",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":182,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":50},"100360753","phase-2-tumor-subtypes-in-subjects-on-folfirinox-with-non-metastatic-pancreatic-cancer-100360753","NCT03977233","Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Histologically or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant metastatic disease.\n* Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.\n* Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core biopsy of the pancreatic mass.\n* Measurable or non-measurable but evaluable (as determined by Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\]) resectable, borderline resectable or unresectable locally advanced PDAC.\n* Subject has adequate performance status as defined by ECOG performance status 0 or 1.\n* Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.\n* Age ≥ 18 years of age.\n* Subject has adequate organ function at study entry.\n* Subject has life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Subject has any evidence of local recurrence or metastatic pancreatic cancer.\n* Other malignancies within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).\n* Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their excipients.\n* Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.\n* Participation in any investigational drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.\n* Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association (NYHA) Class III or IV heart disease\n  * Active infection requiring IV antibiotics\n* Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1\\*28 polymorphism (baseline testing not required).\n* Subject has sensory peripheral neuropathy grade ≥ 2.\n* Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.\n* Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not contraindicated. If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.\n* Subject is pregnant or lactating.\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.","99 Years",{"count":173,"type":20},45,[24],"This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.\n\nChemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.\n\nResearchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.\n\nDepending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.",[177,178,66,179,180,181,29],"Pancreatic Ductal Adenocarcinoma (PDAC)","Cancer of Pancreas","Pancreas Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Non-resectable",[183,181,29,184,185,66],"Pancreatic Ductal Adenocarcinoma","neoadjuvant FOLFIRNOX","FOLFIRINOX","2026-01-09",{"date":188,"type":42},"2026-01-13",{"date":190,"type":42},"2019-06-12",{"date":192,"type":20},"2030-01",{"name":194,"class":49},"UNC Lineberger Comprehensive Cancer Center",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":203,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":206,"conditions":207,"keywords":215,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100545979","pancreatic-cancer-detection-consortium-100545979","NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",true,{"count":205,"type":20},2000,"This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[127,208,209,183,180,210,211,29,212,213,214,66,181],"Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III",[216,217,218,219,220],"Micro RNA","Exosome","Cell free","Early detection","Screening","2025-12-17",{"date":223,"type":42},"2025-12-19",{"date":225,"type":42},"2023-03-15",{"date":227,"type":20},"2026-06-18",{"name":229,"class":49},"City of Hope Medical Center",11,{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":50},"100554229","early-phase-1-clinical-study-of-mrna-vaccine-combined-with-pd-1-inhibitor-as-adjuvant-therapy-for-postoperative-pancreatic-cancer-100554229","NCT06496373","Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer","Clinical Study of XP-004 Personlaized mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer","Inclusion Criteria:\n\n1. Subjects voluntarily signed written informed consent files,Able to comply with the study protocol, in the investigator's judgment\n2. Subjects must be \\>\u002F= 18 years of age at time of informed consent, regardless of gender\n3. Patients who have been confirmed by pathology to have pancreatic malignant tumors and have undergone radical surgery for pancreatic malignant tumors for 1-3 months\n4. No copy number variations (CNVs) or loss of heterozygosity (Loss-of heterozygosity, LOH) were found in HLA-related genes and chromosomal regions by gene sequencing\n5. Histologically confirmed pancreatic cancer samples underwent WES and RNA-seq analyses. Bioinformatics prediction identified at least one neoantigen effectively presented by the patient's HLA type, including those derived from KRAS or TP53 mutations.\n6. According to the investigator's assessment, the patient is unable to tolerate chemotherapy, such as the score of the Eastern Cooperative Oncology Group (ECOG) Performance Scale ≥ 2 points\n\nExclusion Criteria:\n\n1. Has had chemotherapy, traditional Chinese medicine with antitumor indications, or other antitumor therapies deemed to conflict with the current treatment by the investigator within 4 weeks prior to the first administration of the study drug\n2. History of interstitial lung disease (ILD), pulmonary fibrosis\n3. Other serious and\u002For uncontrollable diseases, which may affect the subject's participation in this study, include but not limited to a) a history of severe drug allergy, or is known to be allergic to any tumor vaccine and PD-1 inhibitor formulation components or has had severe allergic reactions to other monoclonal antibodies in the past, b) A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases\n4. Researchers believe that there are other reasons that are not suitable for participating in clinical trials",{"count":239,"type":20},20,[241],"EARLY_PHASE1","This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy for chemotherapy-intolerant patients following radical pancreatic cancer resection.\n\nSecondary objectives focus on evaluating preliminary efficacy through three parameters: 1) XP-004-induced antigen-specific CD4+\u002FCD8+ T cell activation levels, 2) recurrence-free survival (RFS), and 3) overall survival (OS) in post-operative pancreatic cancer patients receiving this combination therapy.",[29,244],"Chemotherapy-intolerant",[246,247,153,248],"Personalized","Neoantigen","Postoperative adjuvant therapy","2025-11-13",{"date":251,"type":42},"2025-11-17",{"date":253,"type":42},"2024-07-16",{"date":255,"type":20},"2027-06-30",{"name":257,"class":49},"Ruijin Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":21,"phases":269,"briefSummary":270,"conditions":271,"keywords":282,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":50},"100572340","optimal-perioperative-pain-control-in-minimally-invasive-abdominal-cancer-surgery-100572340","NCT06731998","Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery","Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery","LapTAP","Inclusion Criteria:\n\n1. Male and female patients age ≥ 18 - 89\n2. Patients scheduled for elective (clinically indicated) hepatic, gastric, biliary, pancreatic, gynecologic, colorectal, other GI Minimally invasive oncologic surgery.\n3. Patients who have provided informed consent to participate in the study.\n4. Patients with an American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Patients undergoing procedures anticipated to last more than 1 hour but less than 8 hours.\n6. Patients able to understand and self-report pain using the designated pain Visual Analog Scale\n\nExclusion Criteria:\n\n1. Patients age less than 18 or ≥ 90\n2. Pre-existing hepatic dysfunction, cirrhosis\n3. Patients with an ASA classification of IV or higher.\n4. Patients with chronic pain disorders or on long-term opioid or analgesic therapy.\n5. Patients with known contraindications to the study drugs or procedures (e.g., allergy to LA or contraindications to LapTAP).\n6. Patients with cognitive impairments or psychiatric conditions that could interfere with pain assessment or understanding of informed consent.\n7. Patients unable to understand the language in which consent and study-related information are provided (The study and the study-related information will be in the English Language)..\n8. Patients who have undergone major surgery within the last 6 months.\n9. Female patients who are pregnant.\n10. Patients currently enrolled in another clinical trial that might interfere with the outcome measures of this study.","89 Years",{"count":268,"type":20},48,[100],"This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered \"Research\" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery:\n\n1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA)\n2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only\n3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.",[272,273,274,275,276,277,29,278,279,280,281],"Oncologic Surgery","Cancer","Cancer Surgery","Hepatic Cancer","Gastric (Cardia, Body) Cancer","Biliary Tract Cancer","Gynecologic Cancers","Gastrointestinal Cancers","Colorectal Cancer","Minimally Invasive Surgical Procedures",[283,284,285,286,287,288,289,290,291],"Laparoscopic Transversus Abdominis Plane Block","Local Anesthetic","Laparoscopic Surgical Procedure","pain management","cancer","cancer surgery","oncologic surgery","perioperative pain management","minimally invasive surgical procedures","2025-09-15",{"date":294,"type":42},"2025-09-18",{"date":296,"type":42},"2025-02-05",{"date":298,"type":20},"2026-12",{"name":300,"class":49},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100604908","phase-3-neoadjuvant-treatment-vs-upfront-surgery-for-left-sided-pancreatic-cancer-100604908","NCT07155629","Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","Neoadjuvant Treatment vs Upfront Surgery for Left Sided Pancreatic Cancer (LEFT-PANC) - a Study Protocol for a Prospective Randomized Multicenter Trial","LEFT-PANC","Inclusion Criteria:\n\n* Resectable left pancreatic cancer according to NCCN criteria\n* Written and informed consent\n* Age \\> 18y\n* ECOG 0-2\n* Fit for surgery\n* Fit for neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* ECOG \\> 2\n* Histology other than ductal adenocarcinoma\n* Unable to give written consent\n* \\\u003C 18y","85 Years",{"count":311,"type":20},381,[313],"PHASE3","Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%. Prognosis is affected by multiple factors including tumor stage, biology, treatment response, and anatomical location. Distal (left-sided) pancreatic cancer, originating from the body or tail of the pancreas, accounts for approximately 20-25% of all pancreatic cancers and has been associated with worse survival than pancreatic head cancer, even when adjusted for stage. This may be due to histological, molecular, and embryological differences, and varied systemic therapy responses.\n\nNeoadjuvant chemotherapy has become increasingly important in managing pancreatic cancer. It may improve outcomes by reducing tumor size, allowing for more complete (R0) resections, treating micrometastatic disease early, and identifying patients unlikely to benefit from surgery. While neoadjuvant therapy is recommended for borderline resectable and locally advanced tumors, randomized trials have not shown benefit for patients with upfront resectable pancreatic head cancer. Importantly, no randomized controlled trials have investigated the benefit of neoadjuvant treatment specifically in patients with upfront resectable left-sided pancreatic cancer, despite its distinct biology and worse prognosis.\n\nRetrospective data suggest neoadjuvant therapy may improve survival in left-sided tumors. A recent multicenter study reported significantly longer overall survival in patients treated with neoadjuvant therapy compared to upfront surgery alone. However, prospective randomized data are lacking.\n\nThis multicenter randomized trial aims to assess whether patients with resectable left-sided pancreatic cancer benefit from neoadjuvant chemotherapy compared to upfront surgery. The study will reflect real-world clinical practice by allowing both commonly used regimens-FOLFIRINOX and Gemcitaine-Nab-paclitaxel -as neoadjuvant options. Previous studies have shown these regimens to be similarly effective, and switching between them due to toxicity or progression is feasible and does not seem to impair surgical outcomes or survival. This study aims to evaluate the benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.",[29],"2025-09-01",{"date":318,"type":42},"2025-09-04",{"date":316,"type":20},{"date":321,"type":20},"2030-08-31",{"name":323,"class":49},"Helsinki University Central Hospital",2,{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":333,"targetDuration":335,"studyType":62,"phases":4,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100605060","oncological-safety-of-spleen-preservation-in-left-pancreatectomy-for-pancreatic-ductal-adenocarcinoma-splendid-100605060","NCT07157605","Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)","Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID): Study Protocol for a Prospective Observational International Multicenter Study","SPLENDID","Inclusion Criteria:\n\n* All consecutive adult patients (≥ 18 years) who undergo an open or minimally invasive (i.e., robot-assisted or laparoscopic) left-sided pancreatectomy with concomitant splenectomy for primary resectable, borderline resectable, and locally advanced left-sided PDAC\n\nExclusion Criteria:\n\n* Tumor involvement or abutment of the spleen",{"count":334,"type":20},94,"5 Years","The goal of this observational study is to determine how often lymph node metastases occur in the splenic hilum and surrounding fat in patients with left-sided pancreatic cancer.\n\nThe main question the study aims to answer is:\n\nIs spleen removal necessary in all cases, or is the risk of lymph node metastases in the fat around the spleen low enough to reconsider this standard practice?\n\nCurrently, spleen removal is part of the standard treatment for patients with left-sided pancreatic cancer to ensure that any potential lymph node metastases in the surrounding fat are also removed. However, the likelihood of metastases in this area is low, and spleen removal carries risks.\n\nThis study is a first step toward changing the treatment approach. If the findings show that metastases in the fat around the spleen are rare, the next step will be a randomized trial to further investigate whether spleen removal is necessary.",[29,338],"Pancreatectomy",[340,341,342,343,344,345],"pancreatic adenocarcinoma","PDAC","left pancreatectomy","distal pancreatectomy","splenectomy","splenic hilum","2025-08-28",{"date":348,"type":42},"2025-09-05",{"date":350,"type":42},"2024-11-28",{"date":352,"type":20},"2031-01-01",{"name":354,"class":49},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",10,{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":363,"targetDuration":4,"studyType":21,"phases":365,"briefSummary":366,"conditions":367,"keywords":372,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":50},"100599197","phase-3-neoadjuvant-vs-upfront-surgery-for-resectable-pancreatic-cancer-and-periampullary-cancer-100599197","NCT07081360","Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Histologically or cytologically confirmed pancreatic head cancer or periampullary carcinoma(endoscopic ultrasound (EUS)-guided biopsy).\n* Clearly resectable disease as defined by National Comprehensive Cancer Network (NCCN) criteria on cross-sectional imaging:\n\nNo involvement or abutment of the celiac artery, common hepatic artery, superior mesenteric artery, or replaced right hepatic artery .\n\nLess than 180 degree interface between tumor and vessel wall of the portal vein or superior mesenteric vein, and patent portal vein\u002Fsplenic vein confluence No evidence of metastatic disease.\n\n* Eastern Cooperative Oncology Group (ECOG)=0-1 \\& American Society of Anesthesiologists (ASA) score \\\u003C4.\n* Written informed consent.\n* Medical history without previous pancreatic resection or pancreatic cancer.\n* Adequate organ function (liver, kidney, bone marrow) (serum creatinine ≤2.0 mg\u002FdL,reference range 0.5-1.20 mg\u002FdL; serum albumin ≥2.5 g\u002FdL, reference range 3.5-5.3; aspartate aminotransferase (AST) ≤95 U\u002FL, reference range 0-38; Alanine aminotransferase (ALT) ≤102 U\u002FL, reference range 0-41; prothrombin time ≤1.8, reference range 0-1.20; partial thromboplastin time ≤1.8, reference range 0.82-1.25; leukocyte count greater than 3.5×109\u002FL, reference range 4.2-9.0; platelet count greater than 100×109\u002FL, reference range 130-400; hemoglobin ≥9 g\u002FdL, reference range 12-16).\n\nExclusion Criteria:\n\n* Borderline resectable or locally advanced pancreatic or periampullary cancer.\n* Tumor at the body or tail of the pancreas.\n* Distant metastases.\n* Prior chemotherapy , surgery or radiotherapy for pancreatic cancer.\n* Severe comorbidities precluding surgery or chemotherapy.\n* Pregnancy or lactation.\n* Other neoplastic diseases (malignant)diagnosed in the past 5 years.\n* Major surgery or traumatic event in the past 28 days.",{"count":364,"type":20},262,[313],"Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesions which are not being detected in early disease status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting.\n\nThere are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and periampullary cancer and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC and periampullary Cancer.\n\nThis randomized controlled trial compares neoadjuvant chemotherapy followed by surgery versus upfront surgery for patients with clearly resectable pancreatic head cancer and periampullary cancer. The study aims to determine if neoadjuvant chemotherapy improves overall survival compared to immediate surgery followed by adjuvant chemotherapy.",[368,369,370,29,371,179],"Pancreas Cancer","Periampullary Cancer","Periampullary Carcinoma Resectable","Ampullary Cancer",[153,373,374],"Neoadjuvant chemotherapy","Pancreaticoduodenectomy","2025-08-24",{"date":377,"type":42},"2025-08-29",{"date":379,"type":42},"2025-07-20",{"date":381,"type":20},"2028-08-20",{"name":383,"class":49},"Minia University",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":393,"conditions":394,"keywords":398,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":50},"100538201","french-assessment-of-mrd-by-liquid-biopsies-in-pdac-patients-frenchmrdpdac-100538201","NCT06287749","French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.\n* Age 18 years or older.\n* Scheduled for curative intent surgical resection.\n\nExclusion Criteria:\n\n* Hereditary pancreatic cancer.\n* Verified distant metastases.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Adult subject to a legal protection\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":392,"type":20},37,"The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.\n\nPrimary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.\n\nSpecifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after\n\n1. curative-intended surgery and\n2. adjuvant chemotherapy.\n\nFRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project",[29,183,395,396,397],"Minimal Residual Disease","Liquid Biopsy","ctDNA",[183,29,395,396,397],"2025-07-07",{"date":401,"type":42},"2025-07-10",{"date":403,"type":42},"2024-03-01",{"date":405,"type":20},"2028-10-31",{"name":407,"class":49},"University Hospital, Montpellier",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":415,"targetDuration":4,"studyType":21,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":50},"100586359","antecolic-versus-retrocolic-gastrojejunostomy-during-whipples-procedure-100586359","NCT06914349","Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure","Antecolic Versus Retrocolic Gastrojejunostomy Following Pancreaticoduodenectomy: a Prospective Randomised Study","Inclusion Criteria:\n\n* Age over 18 years old\n* Elective pancreaticoduodenectomy\n* Signed consent form\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Patients who are participants in other trials that may affect the results of this study\n* Patients who do not consent to participate in the study",{"count":416,"type":20},76,[100],"Aim: This randomized clinical study aims to compare occurrence of DGE in patients undergoing either antecolic or retrocolic gastrojejunostomy following pancreaticoduodenectomy.\n\nMethods: Participants of this study will be patients undergoing pylorus preserving pancreaticoduodenectomy at the Surgical Department of the University Hospital of Larissa. Patients will be randomized to undergo either an antecolic or a retrocolic gastrojejunostomy and the occurrence of DGE will then be compared between the two groups. Individuals younger than 18 or older than 75 years old, as well as patients who do not consent to participate in this trial, will be excluded.\n\nExpected results: Based on available literature, antecolic gastrojejunostomy may be related with a lower incidence of DGE, without a statistically significant difference between the two methods. We aim to show if one of the two methods of gastrointestinal reconstruction (antecolic versus retrocolic) affects DGE.",[29,420],"Pancreas Neoplasms",[422,423,424,425],"Gastrojejunostomy","Whipple's","Antecolic","Retrocolic","2025-06-05",{"date":428,"type":42},"2025-06-06",{"date":430,"type":42},"2025-03-30",{"date":432,"type":20},"2029-03-31",{"name":434,"class":49},"University of Thessaly",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":50},"100588483","evaluate-the-clinical-feasibility-of-a-novel-neoantigen-reactive-cd8-t-cell-nart-detection-technology-for-postoperative-mrd-surveillance-of-pancreatic-cancer-100588483","NCT06941987","Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer","Inclusion Criteria:\n\n* age \\>18\n* Assessd as resectable PDAC before surgical procedure\n* Voluntary to donate tumor samples resected in curative surgery for PDAC\n* Voluntary to participate in the radiological evaluation, tests of serum tumor markers, and the collection of MRD samples according to the study protocol\n* ECOG state (PS) grades ≤ 2\n* Voluntary to sign informed consent and adhering to the requirements and limitations outlined by lCD and this protocol\n* Confimed as pancreatic ductal adenocarcinoma by pathology\n* RO or R1 resection\n* Clinically evalutated eligible for adjuvant therapy\n* Tumor tissue samples meet the requirements of whole exome sequencing (WES)\n\nExclusion Criteria:\n\n* Preoperative imaging examinations show distant metastasis\n* Have received neoadjuvant therapy\n* Have any other active malignancy within 5 years before enrollment, or have any other indolent cancers that did not interfere with the primary cancer assessment in the study without prior approval from the research committee\n* With other physical or mental conditions that may increase the risk of study participation or (in the investigator's judgment) may make the subject ineligible for study participation, including recent (within the past year) or active suicidal ideation\u002Fbehavior or laboratory abnormalities\n* Have participated in other interventional or observational clinical studies",{"count":442,"type":20},66,"The goal of this observational study is to learn about the diagnostic performance of a novel Neoantigen-Reactive CD8+ T cell (NART) technology detecting minimal residual disease (MRD) in postoperative surveillance of pancreatic cancer. The main question it aims to answer is: Is NART a sensitive and accurate detection for MRD? Participants are required to undergo periodic blood sampling and imaging examinations as the protocol specifies.",[395,29],"2025-04-19",{"date":447,"type":42},"2025-04-24",{"date":449,"type":20},"2025-04-20",{"date":451,"type":20},"2027-10-20",{"name":86,"class":49},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":50},"100587981","effect-of-an-enhanced-recovery-after-surgery-program-on-outcomes-after-pancreatoduodenectomy-100587981","NCT06935448","Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy","Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy; Experience From Two Referral Centers in Central Greece.","Inclusion Criteria:\n\n* adult patients\n* diagnosis of pancreatic cancer\n* elective open pancreatic surgery\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* emergency pancreatic surgery\n* other surgical procedures\n* missing data\n* lost to follow-up",{"count":461,"type":20},170,"This study assesses whether patients with pancreatic cancer who undergo surgery experience improved outcomes following the implementation of a multidisciplinary care pathway, specifically an enhanced recovery after surgery (ERAS) program.\n\nThis pathway includes various interventions in the preoperative, intraoperative, and postoperative care of these patients, all aimed at enhancing their health status and postoperative results.",[338,464,29],"Enhanced Recovery After Surgery",[466,467,468,469],"pancreatectomy","enhanced recovery after surgery","pancreatic cancer resectable","outcomes research","2025-04-16",{"date":449,"type":42},{"date":473,"type":42},"2019-07-01",{"date":475,"type":20},"2025-05-30",{"name":434,"class":49},{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":484,"targetDuration":4,"studyType":21,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":50},"100584387","phase-1-personalized-tumor-neoantigen-mrna-therapy-adjuvant-treatment-for-postoperative-pancreatic-cancer-100584387","NCT06888674","Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen MRNA Therapy Combined with PD-1 Antibody and Chemotherapy As Adjuvant Treatment for Postoperative Pancreatic Cancer.","Inclusion Criteria:\n\n1. Pre-Screening Phase Inclusion Criteria (for Radical Surgery and Vaccine Preparation):\n\n   * Subjects meeting all of the following criteria will enter the pre-screening phase for radical surgery and vaccine preparation:\n   * Voluntarily sign the informed consent form (ICF);\n   * Age ≥18 years, regardless of gender;\n   * Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;\n   * ECOG Performance Status score of 0 or 1;\n   * Ability to obtain sufficient fresh tumor tissue samples for whole-exome sequencing (WES) and transcriptome sequencing analysis;\n   * Normal function of major organs (heart, liver, kidneys):\n   * Liver function: Total bilirubin ≤1.5×ULN; ALT\u002FAST ≤2.5×ULN;\n   * Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault formula);\n   * Cardiac function: LVEF ≥50% by echocardiography;\n   * Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;\n   * Ability to comply with the study protocol and follow-up procedures.\n2. Formal Screening Phase Inclusion Criteria (for Study Treatment Initiation):\n\n   * Subjects meeting all of the following criteria will enter the formal screening phase for study treatment:\n   * Voluntarily sign the informed consent form (ICF);\n   * Age ≥18 years, regardless of gender;\n   * Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;\n   * Completion of radical resection (R0 or R1) with no evidence of metastatic disease, malignant ascites, or pleural effusion on imaging 4-12 weeks postoperatively;\n   * ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;\n   * Normal function of major organs (heart, liver, kidneys):\n   * Contraception agreement: Same as pre-screening criteria;\n   * Ability to comply with the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from the study:\n\n* Serum CA 19-9 level \\>180 U\u002FmL within 21 days prior to initiating standard postoperative adjuvant therapy;\n* History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;\n* Concurrent immunosuppressive therapy, defined as regular use of immunosuppressive agents within 4 weeks prior to screening or during the study, including but not limited to:\n\n  1. Severe asthma requiring systemic corticosteroids (≥10 mg\u002Fday prednisone equivalent);\n  2. Active autoimmune disease or immunodeficiency (e.g., rheumatoid arthritis, systemic lupus erythematosus);\n  3. History of primary immunodeficiency;\n  4. Exceptions: Type 1 diabetes, autoimmune hypothyroidism managed with hormone replacement, vitiligo, or psoriasis not requiring systemic therapy;\n* Active bacterial\u002Ffungal infections requiring systemic treatment, or active\u002Flatent tuberculosis (confirmed by interferon-gamma release assay or tuberculin skin test);\n* Active viral infections:\n\n  1. HIV antibody-positive;\n  2. Syphilis (TP antibody-positive with RPR\u002FTRUST confirmation);\n  3. Active hepatitis C (HCV RNA-positive);\n  4. Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU\u002FmL);\n* Acute viral infections:\n\n  1. Herpesvirus infection (unless resolved with crusting \\>4 weeks prior);\n  2. Respiratory viral infection (unless resolved \\>4 weeks prior);\n* Uncontrolled comorbidities:\n\n  1. Symptomatic congestive heart failure (NYHA Class III\u002FIV);\n  2. Unstable angina or arrhythmia requiring treatment;\n  3. Severe coronary\u002Fcerebrovascular disease (e.g., myocardial infarction within 6 months);\n  4. Other conditions deemed exclusionary by the investigator;\n* History of drug abuse, psychiatric disorders, or psychosocial factors impairing informed consent or protocol compliance;\n* History of severe hypersensitivity to vaccines, biologics, or any component of the study drug;\n* Pregnancy or lactation;\n* Other conditions judged by the investigator to preclude safe participation.",{"count":485,"type":20},60,[23,24],"This study is a single-center, open-label clinical study to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard chemotherapy regimen as adjuvant treatment for postoperative resectable pancreatic cancer.",[29],"2025-03-15",{"date":491,"type":42},"2025-03-21",{"date":493,"type":20},"2025-04-01",{"date":495,"type":20},"2029-04-01",{"name":497,"class":49},"Zhejiang University",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":16,"minAge":506,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":521,"locationsCount":4},"100582852","neoadjuvant-chemotherapy-for-elderly-with-pancreatic-head-cancer-100582852","NCT06868693","Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer","Pancreatic Cancer of the Head: Effect of Neoadjuvant Chemotherapy in Elderly People - a Multicenter Observational Study","PEACE","Inclusion Criteria\n\n* Patients aged ≥ 70 years\n* Patients with resectable or BR PDAC who underwent curative treatment (NAT followed by surgery and upfront surgery)\n* Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \\> 2\n* Patients able to provide informed consent, whenever possible\n\nExclusion Criteria\n\n* Patients not meeting the inclusion criteria.\n* Pancreatic cancer of pancreatic body and tail.\n* Patients with metastatic disease.\n* Patients with locally advanced or metastatic pancreatic cancer","70 Years","100 Years",{"count":509,"type":20},240,"The goal of this observational retrospective cohort study is to evaluate the efficacy and safety of neoadjuvant chemotherapy (NAT) in elderly patients with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). The study includes patients aged ≥70 years who have undergone NAT followed by surgery or upfront surgery.\n\nThe main questions it aims to answer are:\n\nDoes NAT improve overall survival (OS) and progression-free survival (PFS) in elderly patients compared to upfront surgery? What is the impact of NAT on R0 resection rates, conversion rates in BR tumors, and the need for vascular resection? How does the toxicity profile of different NAT regimens affect treatment outcomes and patient tolerability? Researchers will compare NAT followed by surgery vs. upfront surgery to determine differences in oncologic outcomes and postoperative complications.\n\nParticipants will:\n\nBe retrospectively identified from hospital records. Be classified based on treatment received (NAT vs. upfront surgery). Undergo data collection on tumor characteristics, treatment regimens, surgical details, and survival outcomes.\n\nThis study aims to refine patient selection criteria for NAT in elderly patients, guiding personalized treatment strategies to optimize survival and quality of life.",[29,213,512,513,514],"Neoadjuvant Therapy","Elderly","Borderline Pancreatic Inoperable Cancer","2025-03-08",{"date":517,"type":42},"2025-03-11",{"date":519,"type":20},"2026-01-01",{"date":298,"type":20},{"name":522,"class":49},"Azienda Unita Sanitaria Locale di Piacenza",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":530,"targetDuration":4,"studyType":21,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":50},"100571642","phase-2-study-of-adjuvant-nimotuzumab-combined-with-nab-paclitaxel-gemcitabine-in-egfr-positive-pancreatic-cancer-100571642","NCT06722911","Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study","Inclusion Criteria:\n\n* 1\\. Able and willing to provide a written informed consent.\n* 2\\. Age 18-75 years old, gender unlimited;\n* 3\\. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;\n* 4\\. Postoperative pathology suggested R0\u002FR1 resection;\n* 5\\. EGFR positive (by immunohistochemistry);\n* 6\\. KRAS gene and CDX-2 protein status must have been determined at baseline (only for post hoc analysis);\n* 7\\. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; platelets≥80×10\\^9\u002FL; hemoglobin≥9.0 g\u002FdL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n* 8\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* 9\\. Postoperative survival is expected to be ≥3 months;\n* 10\\. Fertile subjects are willing to take contraceptive measures during the study period.\n\nExclusion Criteria:\n\n* 1\\. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;\n* 2\\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* 3\\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\\>160mmHg or DBP\\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;\n* 4\\. Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;\n* 5\\. CA199\\>180 U\u002Fml within 21d before adjuvant therapy;\n* 6\\. Known allergy to prescription or any component of the prescription used in this study;\n* 7\\. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);\n* 8 .Other reasons that are not suitable to participate in this study according to the researcher\\'s judgment.",{"count":531,"type":20},57,[24],"This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.",[29],"2024-12-04",{"date":537,"type":42},"2024-12-09",{"date":539,"type":42},"2024-11-15",{"date":541,"type":20},"2028-09-30",{"name":543,"class":49},"Zhejiang Provincial People's Hospital",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":507,"enrollmentInfo":551,"targetDuration":4,"studyType":21,"phases":553,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":4},"100570181","conventional-partial-pancreatoduodenectomy-versus-an-extended-pancreatoduodenectomy-for-pancreatic-head-cancers-100570181","NCT06703905","Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers","Short and Long-term Outcomes of Minimally Invasive Pancreatoduodenectomy Combined with Triangle Operation for Resectable Pancreatic Cancer: an International Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Preoperative: a. Patients with suspected or histologically verified resectable, borderline or locally advanced pancreatic cancer of the pancreatic head (i.e. pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN)-carcinoma or periampullary cancer of the pancreatobiliary-type) ; b. Patients scheduled for elective partial pancreatoduodenectomy (irrespective of neoadjuvant therapy); c. Assumed resectability in accordance with the surgical protocol for experimental and control intervention as judged by the treating surgeon; d. Ability of the subject to understand character and individual consequences of the clinical trial;e.Written informed consent; f. Age ≥ 18 years;\n2. Intraoperative: a.No distant metastases; b.No paraaortic lymph node metastases; c.Intraoperative confirmation that the patient can be operated on according to both surgical methods.\n\nExclusion Criteria:\n\n1. Participation in another interventional trial with the interference of intervention and outcome of this trial;\n2. American Society of Anesthesiologists (ASA) grade \\>3;\n3. Distant metastatic disease .",{"count":552,"type":20},270,[100],"The goal of this clinical trial is to learn if traditional pancreaticoduodenectomy (PD) combined with TRIANGLE (extended PD surgery) can increase disease-free survival (DFS) in patients with pancreatic head cancers compared to traditional minimally invasive PD. The main questions it aims to answer are:\n\n* Does extended PD surgery increase disease-free survival (DFS)?\n* Does extended PD surgery could improve postoperative and long-term quality of life for patients? Researchers will compare extended PD surgery to traditional PD surgery to see if extended PD surgery could extend the survival time of patients.\n\nParticipants will:\n\n* Accept traditional minimally invasive PD surgery or minimally invasive PD combined with TRIANGLE surgery.\n* Visit the clinic once every 3 months for checkups and tests.\n* Keep a diary of their symptoms.",[29],[153,557,558,559],"pancreaticoduodenectomy","Minimally invasive surgery","Heidelberg Triangle","2024-11-21",{"date":562,"type":42},"2024-11-25",{"date":564,"type":20},"2024-12",{"date":566,"type":20},"2028-12",{"name":568,"class":49},"First Affiliated Hospital Xi'an Jiaotong University",{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":576,"targetDuration":578,"studyType":62,"phases":4,"briefSummary":579,"conditions":580,"keywords":586,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":593,"leadSponsor":595,"locationsCount":4},"100567619","spanish-registry-of-quality-indicators-and-adverse-events-of-endoscopic-retrograde-cholangiopancreatography-100567619","NCT06670547","Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Prospective and Multicenter Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","Inclusion Criteria:\n\nAll consecutive patients who have undergone an ERCP at participating centres from 1 November 2024 will be included. An ERCP will be considered to have been performed when an endoscope is introduced to access the duodenal papilla.\n\nThese included patients must meet all of the following criteria:\n\n* Over 18 years of age\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Unavailability of informed consent\n* Impossibility of follow-up.",{"count":577,"type":20},3000,"30 Days","Endoscopic retrograde cholangiopancreatography (ERCP) is a technique which combines endoscopic and radiological vision and allows for therapeutic procedures on pathologies of the pancreas and bile duct.\n\nERCP is a generally well tolerated procedure, nonetheless it is a complex technique that has a higher frequency of complications compared to most endoscopic procedures that can even be life-threatening. These complications are related to patient characteristics, experience of the endoscopist performing the procedure, and specific factors to the technique. Due to its complexity, quality assurance, operator training and auditing are required to increase success and minimize complications.\n\nThere are quality indicators suggested by the main scientific societies in relation to technical aspects and complications, recommending their monitoring and auditing. Most endoscopy units lack records to monitor quality and complications, which prevents the assessment of quality and the identification of areas for improvement.\n\nGiven the lack of evidence of the quality of ERCP in the Spanish population, the investigators will be conducting a multicenter, national prospective study that will include subjects who undergo ERCP.\n\nPatient data and technical aspects of the procedure will be recorded and all included patients will be monitored to identify complications. The quality indicators obtained within the registry will be compared with those established by scientific societies and the relationship between complications and technical factors will be analyzed.",[581,582,583,584,29,181,585],"Choledocholithiasis","Choledocholithiasis With Acute Cholangitis","Cholangiocarcinoma","Sclerosing Cholangitis","Biliary Fistula",[587,588],"ERCP ADVERSE EVENTS","PERFORMANCE MEASURES","2024-10-31",{"date":591,"type":42},"2024-11-01",{"date":591,"type":20},{"date":594,"type":20},"2028-10-30",{"name":596,"class":49},"Germans Trias i Pujol Hospital",{"id":598,"slug":599,"hasResults":11,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":203,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":324},"100554181","early-diagnosis-of-pancreatic-cancer-via-deciphering-multi-modal-immunological-signatures-100554181","NCT06495749","Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures","Inclusion Criteria:\n\n* Sign the informed consent form;\n* Initial diagnosis as patients with pancreatic cancer, patients with benign pancreatic lesions, or healthy controls.\n\nExclusion Criteria:\n\n* History of other malignancies;\n* Presence of organ dysfunction;\n* Concurrent immunodeficiency syndrome, active tuberculosis, HIV infection, etc.;\n* Allogeneic transplantation requiring immunosuppressive therapy;\n* Poor follow-up compliance.",{"count":577,"type":20},"Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls. Peripheral blood samples were collected from newly diagnosed pancreatic cancer patients and healthy individuals. Using techniques such as plasma TCR\u002FBCR-seq, CyTOF, and plasma proteomics, multi-modal individual immune characteristics were obtained and analyzed along with clinical information. An artificial intelligence predictive model was built based on these multi-modal individual immune characteristics to establish an early screening technique for pancreatic cancer. The sensitivity and specificity of this artificial intelligence model for early pancreatic cancer diagnosis were evaluated using an external multicenter sample test set.",[29],[607,153,608,609],"Early diagnosis","Artificial intelligence","Immunity decoding","2024-07-15",{"date":253,"type":42},{"date":613,"type":20},"2024-08-01",{"date":615,"type":20},"2027-12-31",{"name":497,"class":49},{"id":618,"slug":619,"hasResults":11,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":624,"targetDuration":4,"studyType":21,"phases":626,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":50},"100544375","phase-4-the-study-of-huaier-granule-in-postoperative-adjuvant-therapy-of-resectable-pancreatic-cancer-100544375","NCT06368063","The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","Study on the Efficacy and Safety of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age range from 18 to 80 years old, regardless of gender;\n* Pancreatic cancer was diagnosed by histopathology after radical surgery within 12 weeks before enrollment;\n* Did not receive neoadjuvant therapy before surgery and did not receive any adjuvant therapy after surgery;\n* ECOG score 0-3 points;\n* Those who choose to use standard chemotherapy independently based on their own situation, or choose Huaier granules for subsequent treatment, voluntarily participate in and cooperate with various research work, including but not limited to cooperating with treatment and follow-up, cooperating with researchers for data collection, and not actively taking other treatments.\n* The subjects voluntarily signed a written informed consent form before participating in this study.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or to avoid or use Huai er granules with caution (Huaier group);\n* Difficulties in taking oral medication due to active gastrointestinal bleeding, perforation, gastric paralysis, etc;\n* Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.\n* History of merging with other malignant tumors;\n* Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment;\n* Concomitant severe infection;\n* Child Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate\\\u003C90ml\u002Fmin);\n* Pregnant or lactating women or those planning to conceive;\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).",{"count":625,"type":20},642,[627],"PHASE4","The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer",[29],[631,248,632,633],"Huaier granule","Resectable pancreatic cancer","Efficacy and safety","2024-05-07",{"date":636,"type":42},"2024-05-08",{"date":638,"type":42},"2024-05-06",{"date":640,"type":20},"2028-03",{"name":642,"class":49},"Xi'an Jiaotong University",{"id":644,"slug":645,"hasResults":11,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":96,"enrollmentInfo":651,"targetDuration":4,"studyType":21,"phases":652,"briefSummary":653,"conditions":654,"keywords":655,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":668,"leadSponsor":670,"locationsCount":4},"100488242","phase-2-perioperative-platelet-inhibition-with-acetylsalicylic-acid-in-patients-with-resectable-tumors-of-the-pancreatic-head-100488242","NCT05637567","Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","Perioperative Platelet Inhibition With Acetylsalicylic Acid Targeting Intraoperative Tumor Cell Seeding in Patients With Resectable Tumors of the Pancreatic Head - a Randomized, Controlled Multicenter Study","ASAP","Inclusion Criteria:\n\n1. Indication: Patients with (histologically confirmed or clinically suspected) surgically resectable, non-metastatic ductal adenocarcinoma of the pancreatic head\n2. Patients planned for pylorus-preserving partial pancreaticoduodenectomy (PPPD \u002F \"ppWhipple\" \u002F Traverso-Longmire procedure) (conventional or minimally invasive)\n3. Male and female patients aged 18 to 80 years\n4. Written informed consent of the participating person\n5. ECOG≤2\n\nExclusion Criteria:\n\n1. Metastatic disease (distant or peritoneal metastases or lymph node involvement considered distant metastasis (i.e., interaortocaval nodes))\n2. Preoperative use of anticoagulants \u002F thrombolytics (e.g. warfarin, heparin), platelet aggregation inhibitors (e.g. ASA, ticlopidine, clopidogrel), chronic NSAID or metamizole use\n3. Neoadjuvant treatment for locally advanced disease\n4. Presumed necessity of arterial resection (other than gastroduodenal artery)\n5. Advanced liver (INR \\>1.5 or hepatic encephalopathy) or renal failure (stage IV or higher)\n6. Advanced heart disease (NYHA class ≥ 3)\n7. Known hypersensitivity to ASA or to drugs with a similar chemical structure\n8. History of asthma attacks triggered by salicylates or substances with similar effects\n9. Haemorrhagic diathesis, blood coagulation disorders such as haemophilia or thrombocytopenia\n10. Thrombocytosis \\> 450,000 \u002F μL\n11. Methotrexate at a dosage of 15 mg or more per week\n12. Participation in competing trials affecting the effects of the investigational medicinal product (IMP) or outcome measures\n13. Addictive or other medical conditions that do not allow the subject to appreciate the nature and scope of the clinical trial and its potential consequences\n14. Pregnant or breast-feeding women\n15. Women of childbearing potential, except women who meet the following criteria:\n\n    * Post-menopausal (12 months natural amenorrhoea or six months amenorrhoea with serum follicle-stimulating hormone (FSH) \\> 40 U\u002Fml)\n    * Postoperative (six weeks after bilateral ovariectomy with or without hysterectomy)\n    * Regular and correct use of a contraceptive method with a failure rate \\\u003C 1% per year (e.g. implants, depot injections, oral contraceptives, intrauterine devices)\n    * Sexual abstinence\n    * Vasectomy of partner\n16. Indications that the patient is unlikely to comply with the protocol (e.g. unwillingness to cooperate)",{"count":461,"type":20},[24],"This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head. The main question it aims to answer is: Do patients treated perioperatively with aspirin develop less metastasis after curative resection of pancreatic head tumors?\n\nParticipants will be asked to :\n\n* take a daily aspirin tablet starting 1-4 weeks before surgery until 6 months after surgery\n* participate in regular follow-up visits.",[29],[68,656,657,658,659,660,661,662],"pancreatic head cancer","acetylsalicylic acid","aspirin","pancreatic head resection","liver metastases","distant metastases","circulating tumor cells","2023-11-08",{"date":665,"type":42},"2023-11-13",{"date":667,"type":20},"2024-04",{"date":669,"type":20},"2029-03",{"name":671,"class":49},"German Cancer Research Center"]